Analgesia produced by intrathecal administration of the kappa opioid agonist, U-50,488H, on formalin-evoked cutaneous pain in the rat

Eur J Pharmacol. 1990 Nov 13;190(3):287-93. doi: 10.1016/0014-2999(90)94192-z.

Abstract

The antinociceptive activity of the selective kappa opioid agonist U-50,488H, given intrathecally (i.t.) against chemically induced cutaneous pain in rats, was assessed from cumulative dose-response experiments and the formalin test. Three successive i.t. doses of 5, 10 and 35 nmol of U-50,488H produced a gradual reduction of pain scores which was statistically significant at all observation periods. This effect was antagonized significantly by 3 mg/kg i.p. of the opiate antagonists, naloxone and WIN 44,441-3. The analgesia profile showed a clear dose-response relationship. A dose producing 50% 'maximum possible analgesia' of 6.20 nmol (95% confidence interval: 3.05-12.59 nmol) was calculated. The results indicated that cutaneous pain of a chemical/inflammatory nature is highly sensitive to activation of kappa receptors of the spinal cord dorsal horn.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer
  • Analgesia*
  • Analgesics / administration & dosage*
  • Animals
  • Formaldehyde
  • Injections, Spinal
  • Male
  • Pain / chemically induced
  • Pain / drug therapy*
  • Pain Measurement / drug effects*
  • Pyrrolidines / administration & dosage*
  • Rats
  • Skin Diseases / chemically induced
  • Skin Diseases / drug therapy*

Substances

  • Analgesics
  • Pyrrolidines
  • Formaldehyde
  • 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer